Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update.
'It is especially gratifying that at a time when we are advancing our clinical pipeline programs, with our lead program CYB003 in Phase 3 development, the path toward approval and eventual commercialization of psychedelic therapeutics is gaining clarity,' said Doug Drysdale, Chief Executive Officer of Cybin. 'With our expanded intellectual property portfolio, and a number of key partnerships in place, we believe our rigorous research and novel clinical approach can lead to a transformation in how mental health disorders are treated. Now is the time to address the mental health crisis, and we are encouraged by recent sentiment in favor of expediting the regulatory review process for product candidates in development.'
Recent Corporate Highlights
Continued to expand its strategic clinical site partnership ('SPA') program in support of the Phase 3 PARADIGM program. The SPA program is designed to facilitate collaboration among sites, enhance efficiency in trial operations, and improve overall site performance.
Partnered with Thermo Fisher Scientific, a world-class manufacturing partner, to provide U.S.-based manufacturing for the CYB003 program. Cybin broadened its existing strong relationship with Thermo Fisher Scientific to include the development of both the drug substance and drug product capsules for CYB003.
Partnered with Osmind, a leading service provider to psychiatry practices in the U.S., with the objective of accelerating commercial preparation for clinical-stage pipeline. Osmind advances psychiatry through technology and services to bring innovative mental health treatments to patients in need. Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline.
Continued to expand intellectual property portfolio with two additional U.S. patents supporting lead programs CYB003 and CYB004, bringing the total to over 90 granted patents and over 230 pending applications. The recently issued patents are as follows:
U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041.
U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ('IM') injection, including CYB004.
Positive Regulatory Signals and Evolving Acceptance of Potential Therapeutic Value of Psychedelics
Recent statements and hiring decisions by senior U.S. Health and Human Services ('HHS') and FDA officials, in addition to ongoing signs of bipartisan congressional support, suggest an improved forward regulatory environment for psychedelic medicine and therapies, including the potential for accelerated approval pathways.
The Company believes that these developments, together with increased political recognition and public understanding of the science underpinning these programs, have the potential to expedite regulatory pathways and reduce overall risk across its clinical portfolio. Highlights include:
In a recent interview, FDA Commissioner Dr. Marty Makary stated that psychedelic-drug review is a 'top priority' and promised an 'expeditious and rapid review' of clinical data. 1
Drug-policy lawyer, Matthew Zorn, has joined HHS as Deputy General Counsel to work on psychedelics policy. He previously challenged the government on matters such as allowing research on cannabis for veterans with PTSD, preventing tryptamines from being scheduled, and fighting for patient access to psilocybin under Right to Try laws. 2
Navy-SEAL-turned-Congressman Morgan Luttrell recently urged the GOP to 'embrace' compounds such as psilocybin, MDMA and ibogaine to help veterans with PTSD. 3
President Trump's new pick for surgeon general, Dr. Casey Means, wrote in a recent book that people should consider guided-psychedelic therapy. 4
Cybin's Chief Executive Officer Doug Drysdale recently appeared on Fox News and is increasingly sought by media outlets as a trusted commentator. 5
On June 19, 2025, Doug Drysdale will speak in a panel discussion focused on the regulatory landscape and next steps for potential commercialization, at the Psychedelic Science 2025 Conference taking place June 16-20, 2025, in Denver, Colorado. The panel details are as follows:
Panel Title: The Home Stretch: Pivotal Trials and Preparing for Launch
Date and Time: Thursday, June 19, 2025, at 9:30 a.m. MDT (11:30 a.m. EDT)
About Cybin
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
Sources
NewsNation, 'FDA Commissioner Says Research on Psychedelic Treatment 'Top Priority',' interview with FDA Commissioner Dr. Marty Makary, video posted May 16, 2025, https://www.youtube.com/watch?v=KEQFKBME668 (accessed June 9, 2025).
Politico, 'A Psychedelics Hire at HHS,' newsletter article, published May 28 2025, https://www.politico.com/newsletters/future-pulse/2025/05/28/a-psychedelics-hire-at-hhs-00371416 (accessed June 9 2025).
The Wall Street Journal, 'Lawmaker 'Reborn' Through Psychedelic Therapy Wants the GOP to Embrace It,' news article, published May 17 2025, https://www.wsj.com/politics/policy/republican-psychedelic-drug-therapy-fc313ea2 (accessed June 9 2025).
The Associated Press, 'Trump Surgeon General Pick Praised Unproven Psychedelic Therapy, Said Mushrooms Helped Her Find Love,' news article, published May 14 2025, https://apnews.com/article/means-trump-surgeon-general-mushrooms-psychedelic-drugs-72c22ed077409b4bb865214e7ef304a8 (accessed June 9 2025).
Fox News. 'Trump Administration Exploring Potential Benefits of Psychedelic Treatments.' America's Newsroom, correspondent Alexandria Hoff, broadcast June 5 2025. Video clip, 1:58. https://www.foxnews.com/video/6373914669112
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to enroll participants and add additional clinical sites for the PARADIGM program; regulatory statements that suggest an expedited regulatory pathway for Cybin programs; the anticipated approval and commercialization of CYB003 and CYB004; the ability to accelerate commercial preparation of clinical-stage programs through the Company's partnership with Osmind; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ('AIM' or the 'Company') (NYSE American: AIM) today announced the receipt of a warning notification (the 'Letter') from the NYSE American LLC (the 'NYSE American') stating that the Company is not in compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the 'Company Guide') requiring stockholders' equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, 2025, the Company had a stockholders' deficit of negative $3.9 million and has had losses in the most recent five fiscal years ended December 31, 2024. The NYSE American previously issued a warning on December 17, 2024 for the same reasons and has issued the Letter because the deficiency remains as of March 31, 2025, when the Company filed its quarterly report on Form 10-Q for the first quarter of fiscal 2025. On February 26, 2025, the NYSE American accepted a plan submitted by the Company to regain compliance by June 11, 2026. Accordingly, the Company still has until June 11, 2026 to regain compliance. The Company's common stock recommenced trading on the NYSE American on June 17, 2025 under the symbol 'AIM'. The Letter in no way has any effect on such trading and does not affect the Company's business, operations or reporting requirements with the U.S. Securities and Exchange Commission. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company's intention to regain compliance with the listing requirements of the NYSE American and its ability to do so. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date hereof, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@ in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Is Cboe Global Stock Outperforming the Nasdaq?
Cboe Global Markets, Inc. (CBOE) is a leading global exchange operator and financial technology firm, headquartered in Chicago and employing around 1,650 people. With a market cap of $23.6 billion, it spans trading venues across North America, Europe, and Asia-Pacific. Companies with a market value of $10 billion or more are classified as 'large-cap stocks,' Cboe Global holds its place in this category. It leads the U.S. options market and is the originator of the VIX volatility index, giving it a unique edge in volatility-driven trading. Its consistent innovation, regulatory expertise, and scale position it as a key player in capital markets infrastructure, capable of capitalizing on both market volatility and long-term trading trends. Is Palantir Stock Poised to Surge Amidst the Israel-Iran Conflict? 'It Has No Utility': Warren Buffett Doesn't Care How High Gold Goes, He Isn't a Buyer OpenAI CEO Sam Altman Says 'We Are Heading Towards a World Where AI Will Just Have Unbelievable Context on Your Life' Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Cboe Global shares are currently trading 3.6% below its 52-week high of $236.02, which they touched recently on May 8. The stock has climbed 3.6% over the past three months, underperforming the broader Nasdaq Composite's ($NASX) 11.7% rise over the same time frame. However, on a year-to-date basis, CBOE has delivered a standout performance, surging 16.5% and handily outperforming the Nasdaq's modest 1.2% return. The outperformance extends over the longer horizon as well, with CBOE boasting a 34.4% gain over the past 52 weeks, far exceeding the Nasdaq's 9.4% rise during the same period. Since July last year, CBOE has remained above its 200-day moving average and has mostly traded over its 50-day moving average since early April. On May 2, shares of Cboe Global Markets rose over 2% following the release of its Q1 results, which exceeded expectations on both earnings and revenue. The company reported adjusted EPS of $2.50, surpassing consensus estimates by 5.9%, while adjusted revenue came in at $565.2 million, topping forecasts by 1.5%. It upgraded full-year guidance, with revenue growth now projected in the mid-to-high single-digit range, thanks to continued investment in tech platforms, global expansion, and Data Vantage. CBOE's rival, CME Group Inc. (CME), has outperformed the stock and gained 38.5% over the past 52 weeks and 17.2% in 2025. Analysts maintain a cautious outlook on its prospects. CBOE has a consensus rating of 'Hold' from the 17 analysts covering the stock and is currently trading above its mean price target of $225. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
7 hours ago
- Yahoo
Opinion: We needed to get rid of the dairy cartel, not sanctify it in law
By Lawrence L. Herman It never ends. On June 5, Yves-François Blanchet, the Bloc leader in Parliament, tabled Bill C-202, a private member's bill that's yet another regrettable effort to enshrine Canada's Soviet-style supply management system in the statute books. It legislates against any increased imports of dairy products, eggs and poultry — sectors the system protects from foreign competition — under Canada's current or future trade agreements. The Senate fast-tracked the bill, passing it on June 17 after it sailed through the House with virtually unanimous support. It's an unprecedented piece of protectionist legislation that favours this one group of farmers. C-202 is virtually identical to Bill C-282, which a Bloc member tabled in 2021 during the past Parliament. It was passed by the Commons in June 2023 and was still being examined in the Senate last November when Donald Trump was elected. It had been stalled there for almost two years and — mercifully — died on the order paper when this spring's election was called. As well as preventing imports, supply management is a quintessential barrier to internal trade, designed to protect local producers against out-of-province competition, whether in dairy, eggs or poultry. Under the influence of the well-financed dairy lobby, the Trudeau government and all the other parties supported Bill C-282 as it made its way through the House. This time round, however, it's hard to see how the Liberals could have voted in favour of a blatantly protectionist bill completely at odds with the Carney government's core policy of dismantling interprovincial trade barriers — and doing so before July 1, no less. While Blanchet and his Bloc colleagues have remained focused on currying favour with Quebec dairy farmers, there has been a sea change in the geopolitical context, most notably a dramatic deterioration in the Canada-U.S. relationship, with Trump targeting dairy import restrictions among the many trade assaults he's been directing at Canada. For Parliament to raise this protectionist fence higher is downright foolish — as was emphasized by experts over and over again during the debate on C-282 — and would seriously jeopardize our relations with the U.S. at this very sensitive juncture. That alone should have consigned C-202 to the Parliamentary dustbin. But some other factors that are not always fully aired should outrage Canadians when the facts are better understood. Consider the dairy sector as an illustration. First, to make supply management work, over the past 50 years governments at both federal and provincial levels have layered complexities onto the system, creating a mind-numbing process run by vast bureaucracies from coast to coast. This newspaper explained it all in a report compiled by staff about a year ago. At the top of the structure is the Canadian Dairy Commission (CDC) and its Canadian Milk Supply Management Committee (CMSMC). Each year, the CMSMC sets the allowable production volume for Canada as whole and the Commission then divides this up among the provinces, who parcel out the quota to their own producers, distributors, processors and consumers. The CDC then sets the farm-gate price for milk under what's called the National Pricing Formula. While consumers may think of milk as milk, under supply management milk is divided into five different classes and many sub-classes, based on what the milk is used for, whether as a consumer good or for further processing. The CDC applies the National Pricing Formula to set the annual farm-gate price in each class, with the price being different for each milk component — butter fat, proteins and solids. Provincial marketing boards then take all of this and, after even more consultations with industry players, determine who in their province is allowed to produce what, as well as where and to whom it can be sold, in what volume and at what price in that particular province. This goes on, year after year, involving scads of officials. Other industries, meanwhile, manage to decide prices and quantities without regulators' help. The point here isn't to go through all of these bureaucratic intricacies — details can be found in the FP report already referred to and on the CDC website — but to illustrate that in diary alone, the system is inordinately complex, difficult to penetrate, and run by large bureaucracies across the country. All this for the benefit of a few more than 9,000 dairy farms, compared, say, with Canada's 71,000 beef farms and 7,400 pig farms, which operate on the open market and receive no such guarantees. These numbers alone illustrate the inequities of this complex, over-staffed and costly system that exists to protect a small but highly favoured fraction of Canada's agricultural producers. When it comes to who runs the system, there's another set of issues that should outrage Canadians. It's run by insiders, persons with direct connections to the dairy industry, the same industry the system is supposed to regulate. For example, the CDC board is made up of persons with dairy industry connections, the chair being a dairy farmer himself. The Supply Management Committee is also weighted with industry players. At the provincial level, there's the same problem. All members of the Ontario Milk Marketing Board, for example, are dairy farmers, a pattern replicated in the other provinces. It's hard to see where the public interest comes in. Jack Mintz: Don't expect big economic gains from lower interprovincial barriers Bjorn Lomborg: Freer trade isn't dead yet, which is a good thing for all of us All of this should have led to a derailment of Bill C-202 and for the Carney government to start to phase out supply management as an outdated, discriminatory, protectionist system, contrary to the public interest. Though C-202 has passed, the government could hold up the proclamation needed to bring it into force pending further developments in our trading relations. In the meantime, Canadians should be concerned both about supply management itself and about the outsized influence its lobbyists have in Ottawa. Lawrence L. Herman, international counsel at Herman & Associates, is a senior fellow at the C.D. Howe Institute. Sign in to access your portfolio
